key: cord-0738030-2d8klce1
authors: Chatow, Lior; Nudel, Adi; Nesher, Iris; Hemo, David Hayo; Rozenberg, Perri; Voropaev, Hanna; Winkler, Ilan; Levy, Ronnie; Kerem, Zohar; Yaniv, Zohara; Eyal, Nadav
title: In vitro evaluation of the activity of terpenes and cannabidiol against Human Coronavirus E229
date: 2021-03-02
journal: bioRxiv
DOI: 10.1101/2021.03.01.433501
sha: cf1c3a6ece492d766d8caff052de169f954bf2b2
doc_id: 738030
cord_uid: 2d8klce1

The activity of a new, terpene-based formulation, code-named NT-VRL-1, against Human Coronavirus (HCoV) strain 229E was evaluated in human lung fibroblasts (MRC-5 cells), with and without the addition of cannabidiol (CBD). The tested formulation exhibited an antiviral effect when it was pre-incubated with the host cells prior to virus infection. The combination of NT-VRL-1 with CBD potentiated the antiviral effect better than the positive controls pyrazofurin and glycyrrhizin. There was a strong correlation between the quantitative results from a cell-viability assay and the cytopathic effect seen under the microscope after 72 h. To the best of our knowledge, this is the first report of activity of a combination of terpenes and CBD against a coronavirus.

alternative for preliminary research (2, 4, 5). HCoV-229E is associated with various 48 respiratory illnesses ranging from the common cold to severe pneumonia (6). 49

Recently, the potential of phytochemicals, such as terpenes, for use as potent 50 antiviral agents has received considerable attention, especially because these 51 substances are naturally abundant with relatively low toxicity and cost (7). 52

Terpenes are natural, volatile compounds primarily extracted from plants, 53 which contain only carbon, hydrogen and oxygen atoms. In plants, terpenes act as 54 chemoattractants or chemorepellents (8) and are largely responsible for plant 55 fragrances. In animals and humans, terpenes exhibit a variety of pharmacological 56 6 µg/mL, 500 µg/mL and 1000 µg/mL. The cells were incubated for an additional 72 ± 2 105 h at 34°C and 5% CO2. Finally, the cells were subjected to an XTT assay. Based on the 106 results of this work, we determined the non-toxic concentrations of the compounds 107 to be used in the efficacy evaluations: CBD (0.5 µg/mL and 1 µg/mL), NT-VRL-1 (2 108 µg/mL, 5 µg/mL and 10 µg/mL), NT-VRL-1 + CBD ( 10 µg/mL + 1 µg/mL), pyrazofurin 109 (5 µg/mL) and glycerrihizin (400 µg/mL). supplemented with 10% fetal calf serum, and then incubated at 37°C and 5% CO2. 114

The next day, the medium was discarded and 100 µL of EMEM supplemented with 115 1% fetal calf serum was added to the cells, supplemented with the compounds at 116 concentrations previously identified as nontoxic. The cells were incubated for 1 h at 117 34°C and 5% CO2. Next, 1 µL of medium or virus at 100 times the concentration of supplemented with 10% fetal calf serum, and then incubated at 37°C and 5% CO2. 127

The next day, 120 µL of EMEM supplemented with 1% fetal calf serum was added to 128 the wells, supplemented with the compounds at concentrations previously identified 129 as nontoxic. The virus was mixed with the compounds in a U-shaped plate and then 130 incubated for 1 h at 34°C and 5% CO2. Then, 1.2 µL medium or virus at 100 times the 131 concentration of the infective dose was added to the wells. Next, 100 µL of the virus 132 + compounds mixture was added to the cells after medium was removed and the 133 cells were incubated at 34°C and 5% CO2 for an additional 72 ± 2 h. Under an 134 

The non-cytotoxic concentrations of the various compounds were 163 determined as the concentrations that did not lead to excess cell death, as compared 164 to untreated cells. As shown in Figure 1 , the non-toxic concentrations were: CBD ≤ 1 165 µg/mL, NT-VRL-1 ≤ 10 µg/mL, pyrazofurin ≤ 10 µg/mL and glycyrrhizin ≤ 500 µg/mL. With global COVID-19 vaccination in its initial stages, the timeframe for full 207 global vaccination is still unknown. Several population groups, such as the youngest 208 age groups and people with health limitations, will take longer to vaccinate. 209

Therefore, a preventative antiviral treatment to be used in conjunction with vaccines 210 or even temporarily until vaccination or other alternatives become available would 211 be valuable. 212

The objective of this study was to evaluate the anti-viral activity of the NT-213 VRL-1 terpene formulation, with and without CBD, against human HCoV-229E in 214 human lung fibroblasts in vitro. In this study, we report the antiviral activity of the 215 NT-VRL-1 terpene formulation and show that that activity was enhanced when it was 216 applied together with CBD, suggesting either a synergetic or additive effect between 217 the terpene formulation and CBD. Several studies have suggested that 218 phytochemicals found in cannabis may be useful as potential anti-inflammatory 219 agents (22, 23). Such activity may be particularly useful for controlling the cytokine 220 storm syndrome and acute respiratory distress syndrome associated with COVID-19. 221

This study is the first to test cannabis phytochemicals for use against a coronavirus. 222

Pyrazofurin, a natural antiviral compound that has been shown to be 223 effective against SARS-associated coronaviruses (17), was used as positive control. 224

Glycyrrhizin, which has been shown to have antiviral effect against SARS-associated 225 coronaviruses (24), served as the second positive control. 226

The mode of antiviral action of NT-VRL-1 was determined by the addition of 227 the compounds to uninfected lung cells, before or after those cells were inoculated 228

with HCoV-229E. The time-of-addition assays can help us to determine the point(s) 229 at which our compound inhibits HCoV-229E replication. 230

Our results demonstrate that NT-VRL-1's antiviral effect was most 231 pronounced in the pretreatment system, which may indicate that the compounds' 232 antiviral effect is based on the prevention of viral attachment and/or entry. Under 233 these conditions, both CBD (at 0.5-1 µg/mL) and NT-VRL-1 (at 2-10 µg/mL) exhibited 234 observable antiviral effects, as did the positive controls (pyrazofurin at 5 µg/mL and 235 glycyrrhizin at 400 µg/mL). In addition, when CBD (1 µg/mL) and NT-VRL-1 (10 236 µg/mL) were applied together, we observed a synergistic antiviral effect that was 237 even stronger than that observed for the positive controls. 

Mechanisms of coronavirus 258 cell entry mediated by the viral spike protein

In vitro 261 virucidal activity of Echinaforce®, an Echinacea purpurea preparation

Health Organization Coronavirus Disease (COVID-19) Dashboard

Phillyrin (KD-1) exerts anti-viral and 268 anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and 269 human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor 270 kappa B (NF-κB) signaling pathway

Comparative antiviral activity 272 of remdesivir and anti-HIV nucleoside analogs against human coronavirus 273 229E (HCoV-229E)

Coronavirus 229E-related pneumonia in 276 immunocompromised patients

Phytochemicals as antibiotic alternatives to promote growth 279 and enhance host health

Terpenoid metabolism

Terpenoids as source of anti-inflammatory compounds

Monoterpenes with analgesic 284 activity--a systematic review

Antibacterial activity of terpenes and terpenoids present 287 in essential oils

Comparative study on the antiviral 289 activity of selected monoterpenes derived from essential oils

Antiviral activity of monoterpenes beta-pinene and 292 limonene against herpes simplex virus in vitro

Comparative anti-infectious bronchitis virus (IBV) 294 activity of (-)-pinene: effect on nucleocapsid (N) protein

HIV-1-inhibiting activity of the essential oil of Ridolfia 301 segetum and Oenanthe crocata

Antiviral activity of glycyrrhizic acid derivatives against 328 SARS coronavirus